Tag Archives: HMPC

EMA Publishes Public Statement on Allium Cepa L., bulbus

Posted on October 30, 2011 by admin| Leave a comment

EMA Publishes Public Statement on Allium Cepa L., bulbus

Full Text Here

The HMPC/MLWP decided to prepare a Community herbal monograph on Allium cepa L., bulbus as announced in the meeting report from the January 2010 HMPC meeting.
After reviewing information on the products containing Allium cepa L., bulbus and preparations thereof marketed in the Community, it appears that very few products (single-ingredient and combination) are available.
A comprehensive literature search was conducted and available data, including information on products on the market in the Community, are assessed vis-à-vis the requirements laid down in Directive 2001/83/EC and its Annex I, in particular Article 1, Article 10a and Chapter 2a.
The HMPC/MLWP concluded that the following requirements for the establishment of a Community herbal monograph on traditional and well-established herbal medicinal products containing Allium cepa L., bulbus are not fulfilled:
- the requirement laid down in Article 10a of Directive 2001/83/EC that the active substance has a recognised efficacy and an acceptable level of safety and that the period of well-established medicinal use has elapsed
- the requirement laid down in Article 16a(1)(d) of Directive 2001/83/EC that “the period of traditional use as laid down on Article 16c(1)(c) has elapsed”

Based on the above-mentioned information, the HMPC is of the opinion that a Community herbal monograph on Allium cepa L., bulbus cannot be established.
To read more about the assessment carried out, a link is provided to the page where to access the draft assessment report on Allium cepa L., bulbus and its list of references.



For Assistance with Registering Herbal Products in the EU Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  3. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

→ Leave a comment

Posted in Herbal

Tagged , , , , , , , ,

EMA Publishes Herbal Monograph for Glycyrrhiza glabra L.,

Posted on October 29, 2011 by admin| Leave a comment

EMA Publishes Herbal Monograph for Glycyrrhiza glabra L.,

Full Text Here

With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended
Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch, radix (liquorice root)
i) Herbal substance Not applicable.
ii) Herbal preparations

a) Comminuted herbal substance

b) Soft extract (DER 1:0.4-0.5), extraction solvent water

c) Soft extract (DER 3:1), extraction solvent water

Comminuted herbal substance as a herbal tea for oral use.
Herbal preparations in liquid dosage forms for oral use.
The pharmaceutical form should be described by the European Pharmacopoeia full standard term.


For Assistance with Registering Herbal Products in Europe Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  3. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

→ Leave a comment

Posted in Herbal

Tagged , , , , , , ,

EMA Publishes Comments Received on Herbal Monograph, Symphytum Officinale L., radix

Posted on October 28, 2011 by admin| Leave a comment

EMA Publishes Comments Received on Herbal Monograph, Symphytum Officinale L., radix

Full Text Here

With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended
Symphytum officinale L., radix (comfrey root)
i) Herbal substance Not applicable.
ii) Herbal preparations Liquid extract (DER 2:1), extraction solvent ethanol 65% V/V.

Herbal preparations in semi-solid dosage forms for cutaneous use.
The pharmaceutical form should be described by the European Pharmacopoeia full standard term.

Traditional herbal medicinal product used for the symptomatic treatment of minor sprains and bruises.
The product is a traditional herbal medicinal product for use in the specified indication



For Assistance with Registering Herbal Products in the EU Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  3. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

→ Leave a comment

Posted in Herbal

Tagged , , , , , ,

EMA Publish Community Herbal Monograph on Fraxinus Excelsior L

Posted on October 27, 2011 by admin| Leave a comment

EMA Publish Community Herbal Monograph on Fraxinus Excelsior L

Full Text Here

With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended
Fraxinus excelsior L. and Fraxinus angustifolia Vahl, folium (ash leaf)
i) Herbal substance
Not applicable.
ii) Herbal preparations
Comminuted herbal substance

Comminuted herbal substance as herbal tea (decoction or infusion) for oral use. The pharmaceutical form should be described by the European Pharmacopoeia full standard term.



For Assistance with Registration of Herbal Products Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  3. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

→ Leave a comment

Posted in Herbal

Tagged , , , , , ,

EMA Publish Procedure on Publication of HMPC Statements with Community Herbal Monographs are not Established

Posted on September 30, 2011 by admin| Leave a comment

EMA Publish Procedure on Publication of HMPC Statements with Community Herbal Monographs are not Established.

Full Text Here

This procedure has been prepared to clarify the conditions when the Committee on Herbal Medicinal Products (HMPC) shall establish a public statement on an herbal substance which was on the HMPC priority list, in the situation where it does not establish a Community herbal monograph on that herbal substance and preparations thereof.
The publication of this procedure is part of the European Medicines Agency’s initiatives to improve transparency in the regulatory and scientific processes followed by the HMPC in fulfilling its tasks as defined by the European legislation.

This procedure does not address the situations where:
a Community list entry cannot be established
a herbal preparation is not included in a Community herbal monograph
The justification as to why a Community list entry cannot be established together with the relevant Community herbal monograph can be found in the assessment report (AR). For the assessment works carried out so far which had led to the publication of final monographs, the absence of adequate genotoxicity data, as part of the evidence required to demonstrate a safe use, has been the primary justification to the non-establishment of a Community list entry on a herbal substance and/or preparations thereof.
The justification as to why a given herbal preparation is not included in a monograph can be found in the AR and/or in the ‘Overview of comments received during the public consultation’. It cannot be expected that such a justification is available for every possible preparation. Current practice is that justification is provided for preparations which can be found on the market of one or several Member States of the European Union and made known to the Rapporteur either by members of the HMPC/Working Party on Community Monographs and Community List (MLWP) or by interested parties via their comments on draft monographs.



For Assistance with Herbal Product Registration in the UK, EU and USA Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  3. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

→ Leave a comment

Posted in Herbal

Tagged , , , ,

EMA Publish Procedure for Calls for Scientific Data for Use in HMPC Assessment Work

Posted on September 20, 2011 by admin| Leave a comment

EMA Publish Procedure for Calls for Scientific Data for Use in HMPC Assessment Work

Full Text Here

In accordance with Directive 2001/83/EC amended as regards traditional herbal medicinal products through Directive 2004/24/EC (1), it is the task of the Committee on Herbal Medicinal Products (HMPC) to establish a list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products (Article 16f). Furthermore, the HMPC shall establish Community herbal monographs for herbal medicinal products (Article 16h(3)). The HMPC has also undertaken to ensure that monographs and list entries remain up-to-date (scientific state of the art) by assessing regularly the need for their revision (5, 6).
The legislation does not specify how scientific data relating to the assessment work for the monographs and list entries should be identified and compiled. The HMPC discussed a number of possibilities and agreed on a practice subject to 3 conditions:
1. The compilation of data will be a public procedure; and
2. The compilation will take place within a framework of criteria to be predefined by the HMPC (e.g. in relation to literature search strategy); and
3. The compilation shall seek to ensure that a complete set of bibliographic references and/or scientific data will be available to the Rapporteur(s).

No requirements for scientific standards are provided in the legislation and submission by interested parties of bibliographic references and/or scientific data is voluntary. However, some guidance as to the scope of data requested can be provided through the application of Directive 2001/83/EC:
Bibliographic data submitted in relation to well-established medicinal use should provide evidence that the constituent or the constituents of the medicinal product has or have a well-established medicinal use with recognised efficacy and an acceptable level of safety within the meaning of Directive 2001/83/EC as amended (Recital 2 of Directive 2004/24/EC).
Bibliographic data submitted in relation to traditional-use should provide evidence that the medicinal product in question, or a corresponding product has been in medicinal use throughout a period of at least 30 years preceding the date of the application, including at least 15 years within the Community (Article 16c(1)(c)).
In addition, the contributor is expected to submit both favorable and unfavorable data as well as to ensure that the newest publications are taken into account.
Further guidance on the requirements can be found in the HMPC ‘Guideline on non-clinical documentation for herbal medicinal products in applications for marketing authorisation (bibliographical and mixed applications) and in applications for simplified registration’ (2) and the HMPC ‘Guideline on the assessment of clinical safety and efficacy in the preparation of Community herbal monographs for well-established and of Community herbal monographs/entries to the Community list for traditional herbal medicinal products/substances/preparations’ (3).


For Assistance with Registering a Herbal Product in the EU or UK Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  3. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

→ Leave a comment

Posted in Herbal

Tagged , , , , , , , ,

EMA Publishes Procedures on the Systematic Review of Community Herbal Monographs and Supporting Documents

Posted on September 19, 2011 by admin| Leave a comment

EMA Publishes Procedures on the Systematic Review of Community Herbal Monographs and Supporting Documents

Full Text Here

The systematic review (assessment of the need for revision) by the Committee on Herbal Medicinal Products (HMPC) of its Community herbal monographs is laid down in section 3.2 of the ‘Reflection paper on the reasons and timelines for revision of final Community herbal monographs and Community list entries’ (EMA/HMPC/326440/2007). The need for a revision will be considered every 5 years in order to ensure that Community herbal monographs remain up-to-date (scientific state of the art).
This procedure addresses the scope, timelines and documenting aspects of the review and possible subsequent revision. The purpose of this document is to enable a consistent process for all monographs adopted by the HMPC.
The same procedure applies to Community list entries as implied in Article 16f(3) of Directive 2004/24/EC. The revision of Community list entries will take place in parallel to or shortly after the revision of related monographs. When a Community list entry is revised, the Comitology procedure will be followed at the European Commission level after transmission by the EMA.



For Assistance with Registering a Herbal Product in the EU and UK Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  3. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

→ Leave a comment

Posted in Herbal

Tagged , , ,

EMA Publishes Guidance on Companies Seeking Scientific advice on Traditional Herbal Medicinal Products

Posted on September 15, 2011 by admin| Leave a comment

EMA Publishes Guidance on Companies Seeking Scientific advice on Traditional Herbal Medicinal Products

Full Text Here

The HMPC adopts its scientific recommendations on the medicinal uses of herbal substances and herbal preparations (laid down in Community herbal monographs) by either consensus or a majority vote. The members of the HMPC (chosen for their role and experience in the evaluation of herbal medicinal products and representing the national competent authorities) express their divergent position when they do not support the entire content of a monograph. The divergent positions are published on the Agency website, as an appendix to the HMPC opinion. These positions may be valuable information for companies as to the specific approaches taken by some regulatory authorities on a national level. The names of the members who expressed the divergent positions can be obtained upon submission of a request for access to documents according to the ‘EMA Policy on access to documents (related to medicinal products for human and veterinary use).

Note: It should be noted that this document has been produced for guidance only and should be read in conjunction with the relevant legislation and guidance, including:
Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004
Directive 2004/24/EC of the European Parliament and of the Council of 31 March 2004 amending, as regards traditional herbal medicinal products, Directive 2001/83/EC on the Community code relating to medicinal products for human use.
Regulation (EC) No 1905/2005 of the European Parliament and of the Council of 14 November 2005 amending Regulation (EC) No 297/95 on fees payable to the European Medicines Agency
Rules for the implementation of Council Regulation (EC) No 297/95 on fees payable to the European Medicines Agency and other measures (EMA/MB/818152/2009)
HMPC rules of procedures (EMA/HMPC/139800/2004 Rev.2)
EMA policy on the appropriate coordination between the scientific committees of the Agency (Policy 0009, EMA/124704/2005 Rev.1)



For Assistance with Registering a Herbal Product in the UK, USA or EU Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  3. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

→ Leave a comment

Posted in Herbal

Tagged , , ,

EMA Publish Guidance on Systematic Review of Community Herbal Monograph Supporting Documents

Posted on September 14, 2011 by admin| Leave a comment

EMA Publish Guidance on Systematic Review of Community Herbal Monograph Supporting Documents

Full Text Here

The systematic review (assessment of the need for revision) by the Committee on Herbal Medicinal Products (HMPC) of its Community herbal monographs is laid down in section 3.2 of the ‘Reflection paper on the reasons and timelines for revision of final Community herbal monographs and Community list entries’ (EMA/HMPC/326440/2007). The need for a revision will be considered every 5 years in order to ensure that Community herbal monographs remain up-to-date (scientific state of the art).
This procedure addresses the scope, timelines and documenting aspects of the review and possible subsequent revision. The purpose of this document is to enable a consistent process for all monographs adopted by the HMPC.
The same procedure applies to Community list entries as implied in Article 16f(3) of Directive 2004/24/EC. The revision of Community list entries will take place in parallel to or shortly after the revision of related monographs. When a Community list entry is revised, the Comitology procedure will be followed at the European Commission level after transmission by the EMA.



For Assistance with Registration of Herbal products in the EU, UK or USA Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  3. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

→ Leave a comment

Posted in Herbal

Tagged , , ,

EMA Publishes Community herbal monograph on Tanacetum parthenium (L.) Schulz Bip., herba

Posted on September 1, 2011 by admin| Leave a comment

EMA Publishes Community herbal monograph on Tanacetum parthenium (L.) Schulz Bip., herba

Full Text Here

Traditional use
With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended
Tanacetum parthenium (L.) Schulz Bip., herba (feverfew)
i) Herbal substance Not applicable.
ii) Herbal preparations Powdered herbal substance

Herbal preparation in solid dosage forms for oral use.
The pharmaceutical form should be described by the European Pharmacopoeia full standard term.

 

Traditional herbal medicinal product for the prophylaxis of migraine headaches after serious conditions have been excluded by a medical doctor.
The product is a traditional herbal medicinal product for use in specified indication exclusively



For Assistance with Regulating a Herbal Product in the UK, USA or EU Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  3. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

→ Leave a comment

Posted in Herbal

Tagged , , , , , ,

EMA Publishes Concept Paper on using CTD Format in Traditional Herbal Medical Products Applications

Posted on July 22, 2011 by admin| Leave a comment

EMA Publishes Concept Paper on using CTD Format in Traditional Herbal Medical Products Applications

Full Text Here

This concept paper is concerned with the revision of the guideline on the use of the Common Technical Document (CTD) format in the preparation of a registration application for traditional herbal medicinal products (EMEA/HMPC/71049/2007).
This revision pertains to the presentation and content of the Module 3 on Quality (chemical, pharmaceutical and biological information) for traditional herbal medicinal products (THMPs) to help future applicants in their submission.

This guideline is applicable to applications for traditional use registration of THMPs for human use.
The compilation of dossiers for marketing authorisation applications for HMPs is not covered by this guideline. However, guidance provided on modules 2.3 and 3 are also applicable to HMPs applications for marketing authorisation for human and veterinary use.

In the light of experience, there is a need to update this guideline to provide further clarification on the exact location of quality data requirements in the Module 3 on Quality of the CTD and to provide further explanations on the kind of information that is required from applicants at time of application.
Minor changes in the body of the current guideline will be introduced and two annexes will be added. The first annex will be a best practice guide describing the exact location of relevant parts of the documentation and the corresponding guidelines in the CTD Module 3 sections and the second annex will be a Module 3 mock-up.

For Assistance with Registering a Herbal Product in the UK, EU or USA Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  3. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

→ Leave a comment

Posted in Herbal

Tagged , , , , ,

EMA Publishes Community Herbal Monograph on Valeriana Officinalis L., Radix and Humulus Lupulus L., flos

Posted on July 19, 2011 by admin| Leave a comment

EMA Publishes Community Herbal Monograph on Valeriana Officinalis L., Radix and Humulus Lupulus L., flos

Full Text Here

Well-established use

With regard to the marketing authorisation application of Article 10a of Directive 2001/83/EC as amended
Fixed combinations of Valeriana officinalis L., radix (valerian root) and Humulus lupulus L., flos (hop strobiles)
i) Herbal substances
Not applicable
ii) Herbal preparations used in fixed combinations of
a) Dry extracts of valerian root (DER 4-8:1, methanol 45-51% m/m) and hop strobiles (DER 3-10:1, methanol 40-51% m/m)
b) Dry extracts of valerian root (DER 4-7:1, ethanol 70% v/v) and hop strobiles (DER 4-8:1, methanol 40% v/v)

Traditional use

With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended
Fixed combinations of Valeriana officinalis L., radix (valerian root) and Humulus lupulus L., flos (hop strobiles)
i) Herbal substances
Not applicable
ii) Herbal preparations used in fixed combinations of
- Liquid extract (DER 1:6.3) from a mixture of valerian root-hop strobiles (1:1), extraction solvent ethanol 40% v/v
- Liquid extract from a mixture (1:1) of valerian root tincture (DER 1:10), extraction solvent ethanol 53% m/m and hop strobiles liquid extract (DER 1:2.2), extraction solvent ethanol 53% m/m
- Dry extracts
a) Dry extracts of valerian root (DER 4-6:1), extraction solvent water and hop strobiles (DER 3-6:1), extraction solvent water
b) Dry extracts of valerian root (DER 5-7:1), extraction solvent methanol 45% m/m and hop strobiles (DER 5-7:1), extraction solvent water
c) Dry extracts of valerian root (DER 4-5:1), extraction solvent ethanol 60% v/v and hop strobiles (DER 5-9:1), extraction solvent water

For Assistance with the Regulation of a Herbal Product in the UK, EU or USA Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  3. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

→ Leave a comment

Posted in Herbal

Tagged , , , , , , , , ,

EMA Publishes Community herbal monograph on Lavandula angustifolia P. Mill., flos

Posted on July 18, 2011 by admin| Leave a comment

EMA Publishes Community herbal monograph on Lavandula angustifolia P. Mill., flos

Full Text Here

With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended Lavandula angustifolia P. Mill., flos
(lavender flower)
i) Herbal substance
As defined in the Ph. Eur. monograph.
ii) Herbal preparations
a) Comminuted herbal substance
b) Tincture (ratio of herbal substance to extraction solvent 1:5), extraction solvent ethanol 50-60% v/v

For Assistance with Regulating a Herbal Product in the UK, EU or USA Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  3. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

→ Leave a comment

Posted in Herbal

Tagged , , , , , ,

EMA Publishes Community Herbal Monograph for Hamamelis virginiana L., cortex

Posted on July 16, 2011 by admin| Leave a comment

EMA Publishes Community Herbal Monograph for Hamamelis virginiana L., cortex

Full Text Here

With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended Hamamelis virginiana L., cortex; Hamamelidis cortex (hamamelis bark)
i)
Herbal substance
Not applicable
ii)
Herbal preparations
-Dried comminuted herbal substance
-Tincture (Ratio of herbal substance to extraction solvent 1:10), extraction solvent ethanol 45% v/v
-Dry extract (DER 5-7.7:1), extraction solvent ethanol 30% m/m

For Assistance with Regulating a Herbal Product in the UK, EU or USA Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  3. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

→ Leave a comment

Posted in Herbal

Tagged , , , , , ,

EMA Publish Community Herbal Monograph on Comicifuga racemosa (L.) Nutt., rhizoma

Posted on July 7, 2011 by admin| Leave a comment

EMA Publish Community Herbal Monograph on Comicifuga racemosa (L.) Nutt., rhizoma

Full Text Here

Well Established Use

With regard to the marketing authorisation application of Article 10(a) of Directive 2001/83/EC as amended
Cimicifuga racemosa (L.) Nutt., rhizoma (black cohosh)
i) Herbal substance
Not applicable.
ii) Herbal preparations
a) Dry extract (DER 5-10:1), extraction solvent ethanol 58% (V/V)
b) Dry extract (DER 4.5-8.5:1), extraction solvent ethanol 60% (V/V)
c) Dry extract (DER 6-11:1), extraction solvent propan-2-ol 40% (V/V)

For Assistance with Regulating a Herbal Product in the UK, EU or USA Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  3. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

→ Leave a comment

Posted in Herbal

Tagged , , , , , ,

EMA Publish Community Herbal Monograph on Pelargonim Sidoides DC and/or Pelargonium Reniforme Curt.,radix

Posted on July 6, 2011 by admin| Leave a comment

EMA Publish Community Herbal Monograph on Pelargonim Sidoides DC and/or Pelargonium Reniforme Curt.,radix

Full Text Here

With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended
Pelargonium sidoides DC and/or Pelargonium reniforme Curt., radix (pelargonium root)
i) Herbal substance
Not applicable.
ii) Herbal preparations
Liquid extract (DER 1:8-10), extraction solvent ethanol 11% m/m

For Assistance with the regulation of a herbal produt in the EU, UK or USA Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  3. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

→ Leave a comment

Posted in Herbal

Tagged , , , , , , ,

EMA Publish Community herbal monograph on Cola nitida (Vent.) Schott et Endl. and its varieties and Cola acuminata (P. Beauv.) Schott et Endl., semen

Posted on June 16, 2011 by admin| Leave a comment

EMA Publish Community herbal monograph on Cola nitida (Vent.) Schott et Endl. and its varieties and Cola acuminata (P. Beauv.) Schott et Endl., semen

Full Text Here

With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended
Cola nitida (Vent.) Schott et Endl. and its varieties and Cola acuminata (P. Beauv.) Schott et Endl., semen (cola)
i) Herbal substance
Not applicable.
ii) Herbal preparations
a) Powdered herbal substance
b) Liquid extract (DER 1:1), extraction solvent ethanol 60% V/V
c)Tincture (ratio of herbal substance to extraction solvent 1:5), extraction solvent ethanol 60% V/V

For Assistance with Registering Herbal Products in the UK or EU Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  3. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

→ Leave a comment

Posted in Herbal

Tagged , , , , , ,

EMA Publish Community herbal monograph on Oenothera biennis L. & Oenothera lamarckiana L., oleum

Posted on June 15, 2011 by admin| Leave a comment

EMA Publish Community herbal monograph on Oenothera biennis L. & Oenothera lamarckiana L., oleum

Full Text Here

With regard to the marketing authorisation application of Article 10(a) of Directive 2001/83/EC as amended
Oenothera biennis L.; Oenothera lamarckiana L., oleum (evening primrose oil)
i) Herbal substance
Not applicable.
ii) Herbal preparations
Fatty oil obtained from seeds of Oenothera biennis L. or Oenothera lamarckiana L. by extraction and/or expression.

→ Leave a comment

Posted in Herbal

Tagged , , , , , ,

EMA Publishes Public Statement on Syzygium Aromaticum (L.) Merill et L.M Perry, flos

Posted on June 14, 2011 by admin| Leave a comment

EMA Publishes Public Statement on Syzygium Aromaticum (L.) Merill et L.M Perry, flos

Full Text Here

The HMPC/MLWP decided to prepare a Community herbal monograph on Syzygium aromaticum (L.) Merill et L.M. Perry, flos as announced in the 2011 MLWP work programme.
After reviewing information on the products containing Syzygium aromaticum (L.) Merill et L.M. Perry, flos and preparations thereof marketed in the European Union, it appears that no single-ingredient products are available. Furthermore, after consultation with interested parties on priority levels for anticipated assessment works in 2010, a low level of priority was identified for the establishment of a monograph on Caryophylli flos.
The Rapporteur has integrated relevant published data in the joint assessment report on Caryophylli aetheroleum and Caryophylli flos.

Based on the above-mentioned information, the HMPC decided that no Community herbal monograph on Syzygium aromaticum (L.) Merill et L.M. Perry, flos will be established, unless new data are provided.

→ Leave a comment

Posted in Herbal

Tagged , , , , , , ,

EMA Publish Community Herbal Monograph on Oenothera Biennis L., Oenothera Lamarckiana L., oleum

Posted on June 13, 2011 by admin| Leave a comment

EMA Publish Community Herbal Monograph on Oenothera Biennis L., Oenothera Lamarckiana L., oleum

Full Text Here

With regard to the marketing authorisation application of Article 10(a) of Directive 2001/83/EC as amended
Oenothera biennis L.; Oenothera lamarckiana L., oleum (evening primrose oil)
i) Herbal substance
Not applicable.
ii) Herbal preparations
Fatty oil obtained from seeds of Oenothera biennis L. or Oenothera lamarckiana L. by extraction and/or expression.

For Assistance with Registering a Herbal Product in the EU or UK Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  3. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

→ Leave a comment

Posted in Herbal

Tagged , , , , , ,